Brooks-PRI Introduces Biotechnology's Most Complete, Integrated, Fully Automated Molecular Biological Workstation
Tuesday January 14, 5:00 pm ET
Parallab(TM) reduces costs and increases flexibility while simplifying the processing of biological samples.
CHELMSFORD, Mass., Jan. 14 /PRNewswire-FirstCall/ -- Brooks-PRI Automation, Inc. (Nasdaq: BRKS - News), which delivers total automation for semiconductor manufacturing, today announced that its Life Sciences Group has developed the breakthrough Parallab workstation for use in biotechnology research applications. Parallab integrates innovative patent pending technologies that result in previously unrealized low cost per sample, high precision performance, functional flexibility and unattended miniaturized sample processing not attainable on any existing platform.
At the core of this technology is the Nano-Pipettor (NP), which processes 96 reactions in parallel and suits numerous biological applications. Using only nanoliters of reagents per reaction, Parallab can aspirate, mix, thermal cycle, purify and dispense product completely ready for analysis. The NP is then decontaminated and sterilized for repetitive, reproducible operation. This critical decontamination process allows continuous reuse of the NP, thereby eliminating the high consumable costs normally incurred with single use disposables in conventional platforms.
Dr. Steve Gordon, Senior Vice President and General Manager of the Life Sciences Group at Brooks-PRI Automation, states, "We have brought together over a dozen technology innovations in this new product. The resulting integrated robotic system is unique in its ability to process tiny samples with very high precision. The key to the system is that once we get hold of a liquid sample, we never let it go, nor let it evaporate. Our Parallab product has exactly what the Genomics industry has been looking for but heretofore unable to buy."
Parallab is the only product in the market that offers the combined benefits of nanoliter volume liquid transfer, reduced consumables and extensive application flexibility. In addition to its small volume liquid handling technologies, Parallab also uses a proprietary high-speed thermal cycler that greatly reduces the time required to process each sample, thereby increasing the daily sample throughput. Unlike other products that perform only certain functions of Parallab, this unique system integrates multiple processes into one compact, fully automated robotic system. The combination of operations into one platform eliminates the need for other instruments and reduces the use of costly laboratory real estate.
About The Life Sciences Division of Brooks-PRI Automation, Inc.
The Life Sciences Division of Brooks-PRI Automation provides manufacturing equipment and instrumentation for pharmaceutical, biotechnology, agrochemical and clinical laboratories. The company applies its expertise in innovative equipment development to create reliable high throughput processing systems for a wide variety of applications including genomics and drug discovery. Brooks-PRI leverages its engineering skills and knowledge in semiconductor manufacturing to create robust laboratory automation systems that work with 24/7 reliability.
About Brooks-PRI Automation, Inc.
Brooks-PRI (Nasdaq: BRKS - News) delivers total automation. The company's hardware, software and services can manage every wafer, reticle and data movement in the fab, helping semiconductor manufacturers accelerate time-to- market while reducing their risk. Brooks-PRI products are used in virtually every fab in the world. For information, visit brooks-pri.com.
"Safe Harbor" Statement under Section 21E of the Securities Exchange Act of 1934: The foregoing discussion contains forward-looking statements related to future results and speaks only of Brooks-PRI Automation's expectations as of the date of this press release. These include statements concerning the technical and geographic markets for our products and the capabilities of those products, and they involve several known and unknown risks and uncertainties that could cause Brooks-PRI's financial results to differ from expectations. Factors that could cause such differences include, without limitation, the continued success of Brooks-PRI Automation, Inc. (the "Company") in the marketplace, the Company's dependence on the cyclical semiconductor industry, the Company's ability to develop and successfully market products in life science applications, the success of our products in meeting customers' expectations, our ability to compete successfully in a variety of geographic markets, the highly competitive nature and rapid technological change that characterize the industries in which the Company competes, our ability to more effectively align costs and revenues so as to achieve sustained profitability and other risks and uncertainties described in the Company's reports and registration statements filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.
All trademarks contained herein are the property of their respective owners.
For More Information Contact:
Larry Chin Rachel G. Mann
VP of Sales and Marketing Account Executive
Brooks-PRI Automation, Inc. Gray & Rice Public Relations
P: (978) 262-4266 P: (617) 367-0100 ext. 114
larry.chin@brooks-pri.com rgmann@gr2000.com
Investor Contact:
Mark Chung
Director of Investor Relations
Brooks-PRI Automation, Inc.
P: (978) 262-2459
mark.chung@brooks-pri.com
--------------------------------------------------------------------------------
Source: Brooks-PRI Automation, Inc. |
